Compare Lockheed Martin Corporation (LMT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Lockheed Martin Corporation trades at $597.2 (market cap $137.96B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Lockheed Martin Corporation is far larger — about 76.2× Recursion Pharmaceuticals Inc's market cap, and Lockheed Martin Corporation pays a 2.31% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| LMT | RXRX | |
|---|---|---|
Market Cap | $137.96B | $1.81B |
Sector | Industrials | Health |
52-Week High | $676.70 | $6.79 |
52-Week Low | $431.56 | $2.84 |
Enterprise Value | $154.71B | $1.33B |
Dividend Yield | 2.31% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
